MX2024009858A - Compuestos y radioligandos para direccion al receptor de neurotensina y usos de los mismos - Google Patents

Compuestos y radioligandos para direccion al receptor de neurotensina y usos de los mismos

Info

Publication number
MX2024009858A
MX2024009858A MX2024009858A MX2024009858A MX2024009858A MX 2024009858 A MX2024009858 A MX 2024009858A MX 2024009858 A MX2024009858 A MX 2024009858A MX 2024009858 A MX2024009858 A MX 2024009858A MX 2024009858 A MX2024009858 A MX 2024009858A
Authority
MX
Mexico
Prior art keywords
targeting
compounds
radioligands
solvate
compositions
Prior art date
Application number
MX2024009858A
Other languages
English (en)
Spanish (es)
Inventor
Fa Liu
Original Assignee
Full Life Tech Hk Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Full Life Tech Hk Limited filed Critical Full Life Tech Hk Limited
Publication of MX2024009858A publication Critical patent/MX2024009858A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0474Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0497Organic compounds conjugates with a carrier being an organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2024009858A 2022-02-18 2024-08-12 Compuestos y radioligandos para direccion al receptor de neurotensina y usos de los mismos MX2024009858A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263311621P 2022-02-18 2022-02-18
PCT/US2023/013314 WO2023158802A1 (en) 2022-02-18 2023-02-17 Compounds and radioligands for targeting neurotensin receptor and uses thereof

Publications (1)

Publication Number Publication Date
MX2024009858A true MX2024009858A (es) 2024-11-08

Family

ID=87579080

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024009858A MX2024009858A (es) 2022-02-18 2024-08-12 Compuestos y radioligandos para direccion al receptor de neurotensina y usos de los mismos

Country Status (11)

Country Link
US (2) US12145926B2 (https=)
EP (1) EP4479040A1 (https=)
JP (1) JP2025506705A (https=)
KR (1) KR20240150464A (https=)
CN (1) CN119136796A (https=)
AU (1) AU2023221977A1 (https=)
CA (1) CA3243418A1 (https=)
CL (1) CL2024002422A1 (https=)
IL (1) IL314786A (https=)
MX (1) MX2024009858A (https=)
WO (1) WO2023158802A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4479040A1 (en) 2022-02-18 2024-12-25 Full-Life Technologies HK Limited Compounds and radioligands for targeting neurotensin receptor and uses thereof
WO2025146126A1 (en) * 2024-01-04 2025-07-10 Full-Life Technologies Hk Limited Preparation method of compounds targeting neurotensin receptor

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5021556A (en) 1987-07-22 1991-06-04 Neorx Corporation Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides
US5075099A (en) 1988-05-31 1991-12-24 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
US5367080A (en) 1990-11-08 1994-11-22 Sterling Winthrop Inc. Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods
DE4307983A1 (de) 1993-03-13 1994-09-15 Beiersdorf Ag Wirkstoffe und kosmetische und dermatologische Zubereitungen
FR2732967B1 (fr) * 1995-04-11 1997-07-04 Sanofi Sa 1-phenylpyrazole-3-carboxamides substitues, actifs sur la neurotensine, leur preparation, les compositions pharmaceutiques en contenant
US5886142A (en) 1997-05-20 1999-03-23 Thomas Jefferson University Radiolabeled thrombus imaging agents
EP2740726A1 (en) * 2012-12-07 2014-06-11 3B Pharmaceuticals GmbH Neurotensin receptor ligands
RU2743781C2 (ru) 2014-06-10 2021-02-25 3Б Фармасьютикалз Гмбх Конъюгат, содержащий лиганд рецепторов нейротензина, и его применение
EP3279197A1 (en) 2016-08-03 2018-02-07 Friedrich-Alexander-Universität Erlangen-Nürnberg Diagnosis, treatment and prevention of neurotensin receptor-related conditions
EP4479040A1 (en) 2022-02-18 2024-12-25 Full-Life Technologies HK Limited Compounds and radioligands for targeting neurotensin receptor and uses thereof

Also Published As

Publication number Publication date
JP2025506705A (ja) 2025-03-13
EP4479040A1 (en) 2024-12-25
US12145926B2 (en) 2024-11-19
US20240287046A1 (en) 2024-08-29
WO2023158802A1 (en) 2023-08-24
CN119136796A (zh) 2024-12-13
US20250026739A1 (en) 2025-01-23
AU2023221977A1 (en) 2024-08-15
IL314786A (en) 2024-10-01
CA3243418A1 (en) 2023-08-24
KR20240150464A (ko) 2024-10-15
CL2024002422A1 (es) 2024-12-06

Similar Documents

Publication Publication Date Title
MX2024009858A (es) Compuestos y radioligandos para direccion al receptor de neurotensina y usos de los mismos
JP7219497B2 (ja) Psma結合剤及びその使用
MX2021005808A (es) Complejos macrociclicos de radionucleidos alfa-emisores y su uso en radioterapia focalizada de cancer.
MX2021013055A (es) Inhibidores de antigenos de membrana especificos de prostata (psma) como agentes diagnosticos y terapeuticos con radionuclidos.
ZA202006137B (en) Substituted imidazolidin-2-one derivatives as prmt5 inhibitors
BR112022012641A2 (pt) Compostos tricíclicos substituídos
PH12021552362A1 (en) Estrogen receptor degrading protacs
MX2022013054A (es) Derivados de imidazolidinona y uso medico de los mismos.
MY197419A (en) Psma-targeted radiopharmaceutical for diagnosing and treating prostate cancer
RU2011139107A (ru) Специфические соединения диарилгидантоина и диарилтиогидантоина
MX2024005950A (es) Radioligandos escindibles para dirigirse a receptores de la superficie celular y sus usos.
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
NZ544583A (en) Bicyclic peptide imaging agents for in vivo diagnosis or imaging of a disease or condition associated with angiogenesis
EP4663637A3 (en) Novel deuterium substituted positron emission tomography (pet) imaging agents and their pharmacological application
MX2009005292A (es) Metodo de radiosensibilizacion de tumores usando un agente radiosensibilizante.
ZA202107431B (en) Para-aminohippuric acid (pah) as a renal protective substance
MX2020002429A (es) Compuestos para reducir la viscosidad de las formulaciones biologicas.
PH12022550441A1 (en) Azaheteroaryl compound and application thereof
MX2023013715A (es) Regímenes de dosis de ecubectedina.
BR112023005443A2 (pt) Derivado de y-carbolina fundido substituído heterocíclico, método de preparação do mesmo, intermediário do mesmo e uso do mesmo
MX2024014994A (es) Macrociclos de indazol y su uso
JOP20250057A1 (ar) مركبات لعلاج السرطان
RU2012114146A (ru) Нерадиоактивные фосфолипидные соединения, композиции и способы их применения
MX2024000999A (es) Antagonista de molécula pequeña de lpa1.
TW200413009A (en) Biphenyls and fluorenes as imaging agents in alzheimer's disease